Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)

• Status: Completed
• Trial end date: 2010-04-28
• Target enrollment: 0
• Participant gender: All

Summary

A clinical study to determine the safety, efficacy and the way sitagliptin works in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Participant has type 2 diabetes mellitus

• Males

• Females who are highly unlikely to become pregnant

• Participants poorly controlled without taking any, or taking one or two oral antidiabetic medications

Exclusion Criteria:

• Participant has a history of type 1 diabetes mellitus or history of ketoacidosis

• Participant required insulin therapy within the prior 8 weeks

• Participant is on or has been taking TZDs such as Actos® (pioglitazone) or Avandia® (rosiglitazone) within the prior 12 weeks of the screening visit